<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical characteristics of patients with a variety of tumor types and a median survival of 6 months or less</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical characteristics of patients with a variety of tumor types and a median survival of 6 months or less</h1>
<div class="graphic"><div class="figure"><div class="ttl">Clinical characteristics of patients with a variety of tumor types and a median survival of 6 months or less</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="50%"></colgroup> <tbody> <tr> <td class="subtitle1">Solid cancer by site</td> <td class="subtitle1">Clinical factors</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Breast cancer</td> </tr> <tr> <td class="indent1">Any metastatic breast carcinoma with one or more of the following presentations:</td> <td> <p>KPS &lt;60 (ECOG performance status &gt;2)</p> <p>Serum calcium &gt;11.2 mg/dL</p> <p>Epidural spinal cord compression with decreased ability to walk</p> <p>Serum C-reactive protein &gt;10 mg/L and serum albumin &lt;3.5 g/dL</p> Peritoneal or leptomeningeal metastases</td> </tr> <tr> <td class="indent1">Any metastatic breast carcinoma with three or more of the following presentations:</td> <td> <p>KPS &lt;80 (ECOG performance status ≥2)</p> <p>Serum LDH &gt;500 international units/L</p> <p>Any liver metastasis</p> <p>At least 2 sites of metastases</p> <p>Disease-free interval from initial presentation to metastatic disease of &lt;24 months</p> <p>Recurrent or refractory disease after initial chemotherapy</p> Estrogen receptor-negative/progesterone receptor-negative tumor</td> </tr> <tr> <td class="indent1">Metastatic breast carcinoma with brain metastases and one or more of the following presentations:</td> <td> <p>KPS &lt;80 (ECOG performance status ≥2)</p> <p>≥2 brain metastases plus extracranial metastases</p> Tumor both estrogen receptor and progesterone receptor-negative </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Primary brain cancer</td> </tr> <tr> <td class="indent1">Glioblastoma with one or more of the following presentations:</td> <td> <p>KPS &lt;70 (ECOG performance status ≥2)</p> <p>Suboptimal surgical resection or unresectable disease</p> Progressive or refractory disease despite initial treatment (unresponsive to treatment)</td> </tr> <tr> <td class="indent1">Glioblastoma with two or more of the following presentations:</td> <td> <p>KPS &lt;90 (ECOG performance status ≥1)</p> <p>Age &gt;55 years</p> <p>Recurrent disease after initial treatment</p> <p>Lesion in critical hemispheric brain region</p> <p>Tumor volume &gt;50 cm<sup>3</sup> prior to resection</p> <p>Hemoglobin &lt;12 g/dL</p> Platelet count &gt; upper limit normal</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Digestive system neoplasms</td> </tr> <tr> <td class="subtitle3_left" colspan="2">Colorectal cancer</td> </tr> <tr> <td class="indent1">Metastatic colorectal cancer with one or more of the following presentations:</td> <td> <p>KPS &lt;70 (ECOG performance status ≥2)</p> <p>Age &gt;75 years</p> Brain metastases with KPS &lt;80, age &gt;70 years, extracranial metastases, or ≥2 brain lesions</td> </tr> <tr> <td class="indent1">Metastatic colorectal carcinoma with two or more of the following presentations:</td> <td> <p>KPS &lt;90 (ECOG performance status ≥1)</p> <p>Peritoneal carcinomatosis</p> <p>&gt;2 metastatic sites</p> <p>Malignant ascites</p> Chemotherapy - refractory disease </td> </tr> <tr> <td class="subtitle3_left" colspan="2">Esophageal and gastric cancers</td> </tr> <tr> <td class="indent1">Locally advanced or metastatic esophageal or gastric cancer with one or more of the following presentations:</td> <td> <p>KPS &lt;80 (ECOG performance status &gt;1)</p> Recurrent or refractory disease, with disease-free interval &lt;6 months</td> </tr> <tr> <td class="indent1">Locally advanced or metastatic esophageal or gastric cancer with two or more of the following presentations:</td> <td> <p>KPS &lt;90 (ECOG performance status ≥1)</p> <p>Liver metastases</p> <p>Peritoneal metastases</p> <p>Serum alkaline phosphatase &gt;100 units/L</p> <p>Serum LDH &gt;200 international units/L</p> Serum hemoglobin &lt;11 g/dL</td> </tr> <tr> <td class="subtitle3_left" colspan="2">Hepatobiliary and pancreatic cancers</td> </tr> <tr> <td class="indent1">Locally advanced or metastatic cholangiocarcinoma, gallbladder carcinoma, or pancreatic cancer with one or more of the following presentations:</td> <td> <p>KPS &lt;90 (ECOG performance status ≥1)</p> <p>Biliary obstruction with jaundice</p> <p>Recurrent or refractory disease after initial chemotherapy</p> <p>Liver, peritoneal, or distant metastases</p> <p>Portal vein thrombosis or other vascular invasion</p> <p>Gross residual disease (visible cancer) after resection</p> <p>Poorly differentiated or infiltrating disease</p> <p>Serum albumin &lt;3.5 g/dL or &gt;10% weight loss</p> <p>Serum LDH &gt;500 international units/L</p> <p>Episode of extremity venous thromboembolism or pulmonary embolization</p> Malignant ascites</td> </tr> <tr> <td class="indent1">Any hepatocellular carcinoma with one or more of the following presentations:</td> <td> <p>KPS &lt;60 (ECOG performance status &gt;2)</p> <p>End-stage cirrhosis</p> <p>Large tumor size (maximum tumor diameter &gt;10 cm or tumor volume &gt;70% liver volume)</p> Any brain metastasis</td> </tr> <tr> <td class="indent1">Unresectable locally advanced or metastatic hepatocellular carcinoma with two or more of the following presentations:</td> <td> <p>KPS &lt;90 (ECOG performance status ≥1)</p> <p>Extrahepatic metastases</p> <p>Moderate to severe symptomatic cirrhosis (eg, jaundice, ascites, fatigue, or bleeding)</p> <p>Alpha-fetoprotein level ≥400 ng/mL</p> Portal vein thrombosis</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Head and neck neoplasms</td> </tr> <tr> <td class="indent1">Recurrent, refractory, or metastatic head and neck squamous cell carcinoma with one or more of the following presentations:</td> <td> <p>KPS &lt;90 (ECOG performance status ≥1)</p> <p>Recurrence of disease with any metastases &gt;10% weight loss</p> <p>Muscle invasion or residual tumor at primary site</p> <p>Pretreatment hemoglobin &lt;11 g/dL</p> Serum calcium &gt;11.2 mg/dL</td> </tr> <tr> <td class="subtitle3_left" colspan="2">Melanoma</td> </tr> <tr> <td class="indent1">Advanced or metastatic melanoma with one or more of the following presentations:</td> <td> <p>KPS &lt;80 (ECOG performance status ≥2)</p> <p>Serum LDH &gt;2 x the upper limit of normal</p> <p>Serum calcium &gt;11.2 mg/dL</p> <p>Metastasis to the brain or spine</p> Metastases to liver and one other site</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Non-small cell lung cancer</td> </tr> <tr> <td class="indent1">Any locally advanced or metastatic non-small cell lung cancer with one or more of the following presentations:</td> <td> <p>KPS &lt;70 (ECOG performance status &gt;2)</p> <p>Weight loss of &gt;5% or serum albumin &lt;3 g/dL</p> <p>Liver metastases</p> <p>Bone or bone marrow metastases</p> <p>Brain metastases with neurological symptoms, KPS &lt;70, age &gt;65 years, or extracranial metastases</p> <p>Pericardial effusion</p> <p>Pleural effusion with evidence of distant metastases</p> <p>Serum hemoglobin &lt;12 g/dL</p> <p>Serum calcium &gt;11.2 mg/dL</p> Age &gt;70 years with pleural effusion, hypoalbuminemia, elevated serum lactate dehydrogenase, or hyponatremia (levels outside the normal range)</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Urogenital neoplasms</td> </tr> <tr> <td class="subtitle3_left" colspan="2">Female genital neoplasms</td> </tr> <tr> <td class="indent1">Locally advanced or metastatic ovarian, uterine endometrial, or uterine cervical cancer with regional or distant spread, and one or more of the following presentations:</td> <td> <p>KPS &lt;60 (ECOG performance status &gt;2)</p> <p>Serum calcium &gt;11.2 mg/dL</p> <p>Brain metastases plus extracranial lesion or KPS &lt;70 or ≥2 brain metastases</p> <p>Intestinal obstruction without successful repair, or urinary tract obstruction with stent placement</p> Unresectable disease due to location of disease or comorbid illness</td> </tr> <tr> <td class="indent1">Locally advanced or metastatic ovarian, uterine endometrial or uterine cervical cancer with regional or distant spread, and two or more of the following presentations:</td> <td> <p>KPS &lt;80 (ECOG performance status &gt;1)</p> <p>Recurrent or refractory disease (unresponsive to treatment)</p> <p>Disease-free interval from diagnosis to disease recurrence or persistence of &lt;6 months</p> <p>Suboptimal resection with bulky residual disease</p> <p>Significant weight loss (&gt;5%)</p> Extra-abdominal metastases</td> </tr> <tr> <td class="subtitle3_left" colspan="2">Prostate cancer</td> </tr> <tr> <td class="indent1">Hormone-refractory metastatic prostate cancer with one or more of the following presentations:</td> <td> <p>KPS &lt;60 (ECOG performance status &gt;2)</p> <p>KPS &lt;80 (ECOG performance status &gt;1) or significant fatigue, plus hemoglobin &lt;12 g/dL</p> <p>Hemoglobin &lt;10 g/dL</p> Spinal cord compression with decreased ambulation</td> </tr> <tr> <td class="subtitle3_left" colspan="2">Bladder and renal cell carcinoma</td> </tr> <tr> <td class="indent1">Locally advanced or metastatic bladder or renal cell carcinoma with one or more of the following presentations:</td> <td> <p>KPS &lt;70 (ECOG performance status &gt;2)</p> <p>Brain metastases with ≥2 metastases, or extracranial metastases</p> Serum calcium &gt;11.2 mg/dL</td> </tr> <tr> <td class="indent1">Locally advanced or metastatic bladder or renal cell carcinoma with three or more of the following presentations:</td> <td> <p>KPS &lt;80 (ECOG performance status ≥2)</p> <p>Hemoglobin &lt;11.5 g/dL</p> <p>Serum LDH &gt;300 international units/L or alkaline phosphatase &gt;220 units/L</p> <p>Disease-free interval from initial presentation to metastatic disease or disease progression ≤1 year</p> Visceral metastases</td> </tr> </tbody></table></div><div class="graphic_lgnd">Presentations associated with a median survival of six months or less.</div><div class="graphic_footnotes">KPS: Karnofsky Performance Status; ECOG: Eastern Cooperative Oncology Group. LDH: lactate dehydrogenase.</div><div class="graphic_reference">Modified with permission from: Salpeter SR, Malter DS, Luo EJ, et al. Systematic review of cancer presentations with a median survival of six months or less. J Palliat Med 2012; 15:175. Copyright © 2012 Mary Ann Liebert, Inc.</div><div id="graphicVersion">Graphic 87452 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
